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Abstract: Breast cancer is the second most common cause of brain metastases and 
deserves particular attention in relation to current prolonged survival of patients with 
metastatic disease. Advances in both systemic therapies and brain local treatments (surgery 
and stereotactic radiosurgery) have led to a reappraisal of brain metastases management.  
With respect to this, the literature review presented here was conducted in an attempt to 
collect medical evidence-based data on the use of whole-brain radiotherapy for the 
treatment of brain metastases from breast cancer. In addition, this study discusses here the 
potential differences in outcomes between patients with brain metastases from breast 
cancer and those with brain metastases from other primary malignancies and the potential 
implications within a treatment strategy. 
Keywords: whole brain radiation therapy; breast cancer; brain metastases; controlled 
extra-cranial disease; overall survival 
 
1. Introduction 
In the last decade, the management of brain metastases (BM) has changed radically. Historically, 
whole brain radiation therapy (WBRT) was the main treatment modality used for patients with BM, 
and the median survival of untreated patients was one month [1]. However, improvements in surgery 
and the extensive use of new technologies for local treatment, as well as improvement in systemic 
therapies, has led to the reconsideration of treatment strategies, by taking into account the established 
prognostic factors and by selecting subgroups of long-term survivors for whom intracranial control has 
become the major endpoint of treatment and, thus, for whom WBRT alone is no longer suitable. 
In addition to these prognostic factors, due to different natural histories and responses to treatment 
according to the histological type and molecular characteristics of the primary tumor, the primary site 
has become a determining factor in the therapeutic decision. Indeed, diagnosis-specific classifications 
have highlighted the importance of the primary site in determining differences in prognostic factors for 
survival, as well as in median survival (median survival: 25 and 13–17 months for graded prognostic 
assessment (GPA) 4 breast cancer (BC) and other primaries, respectively) [2]. 
However, international guidelines are based on randomized controlled studies involving no more 
than 10% of patients with BM from BC [3,4]. In addition, there are no randomized controlled trials 
conducted in patients with BM from BC. As findings from diagnosis-specific classifications are 
basically different according to the primary site [2], it could be hypothesized that results from the 
above-mentioned randomized controlled trials (RCTs) would have been different in a population 
composed exclusively of patients with BM from BC. Therefore, this review focuses on evidence-based 
medicine for the use of WBRT in the management of BM from BC and will discuss the application of 
international guidelines for BM management in patients with BC, particularly related to WBRT. 
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2. Results 
Therapeutic modalities for BM include surgery, stereotactic radiosurgery (SRS), WBRT, systemic 
therapies or a combination of these methods. 
2.1. Whole Brain Radiation Therapy (WBRT) Alone 
It was shown that WBRT, compared to the best supportive care for BM, slightly improved median 
overall survival (3–6 months vs. 1 month, respectively) [1,5]. A complete or partial response and an 
improvement in neurological symptoms were reached in 30%–60% of cases, with variable definitions 
of these criteria among the studies [6]. Two studies assessed prognostic factors associated with WBRT 
response [7,8] and found BM volume to be the most important factor and not BM number. In addition, 
Nieder et al. [7] found that patients with BC (as with those with non-small cell lung cancer) were more 
likely to present a sustainable response to WBRT compared to those with other histologies. Several 
authors have retrospectively investigated the response rate to WBRT in patients with BM from BC 
(mostly multiple BM) and reported a 65%–82% response rate [7,9] with a recurrence rate between 0% 
and 50% (Table 1) [7,10]. 
Table 1. Studies assessing Whole Brain Radiation Therapy (WBRT) alone in patients with 
brain metastases (BM) from breast cancer (BC). 
Study Ref. N 
BM 
number 
Radiation 
schedule 
Response rate * 
(%) 
Recurrence  
rate (%) 
Nieder et al., 1997 [7] 46 Median:4 30 Gy/10 f 65 a 0 
Ogura et al., 2003 [9] 36 Multiple 
−30 Gy/10 f 
−50 Gy/25 f 
Boost: 10 pts 
82 b 32 
Mahmoud-Ahmed et al., 
2002 
[10] 116 
Single:20  
2–3:38  
4–9:50  
>9:8 
30 Gy/10 f NR 50 
Le Scodan et al., 2007 [11] 117 Multiple 30 Gy/10 f NR 42.5 
Abbreviations: N, number of patients; pts, patients; WBRT, whole brain radiation therapy; BM, brain 
metastases; BC, breast cancer; f, fraction; NR, not reported; * Volumetric response was defined as the 
following: a complete remission = complete disappearance of a contrast-enhancing lesion on CT-scan; partial 
remission = volume reduction of >50%; progression = volume increase of >25%; the remaining were scored 
as no change; and b not defined. 
2.2. Protraction 
In order to improve brain control and survival while minimizing delayed side effects, many studies 
have compared different radiation therapy schemes used on patients with mixed primaries [6,12–15]. 
No difference in either the overall survival rate or acute toxicity was observed among the various 
fractionation schemes studied. However, none of these trials reported data related to intracerebral 
progression-free survival, tumor response rate or quality of life based on a validated questionnaire. 
Nonetheless, data from retrospective studies [16,17] seem to favor schemes with lower doses per 
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fraction, which would evidently result in fewer late neurocognitive side effects. The results of one 
retrospective study [18] comparing two fractionation schemes for BM from BC led to the same 
conclusions. Usual schemes range from 30 Gy/10 fractions to 40 Gy/20 fractions irrespective of the 
primary malignancy. 
2.3. WBRT and Radiosensitizers 
Four RCTs (including more than 20 patients with BM from BC) and one meta-analysis involving 
2217 patients tested the association of WBRT with several radiosensitizers. Results showed a greater 
incidence of toxicity without any benefit in terms of local control or survival (Table 2) [19–22]. 
The use of efaproxiral generated interest in a subgroup of patients with BM from BC. In an RCT  
by Suh et al., the significant impact of efaproxiral was observed on the median survival (which was 
doubled) of pre-stratified patients with BC, and there was an increase of 13% in terms of tumor 
response for the population with lung/breast (p = 0.01) [21,23]. Subsequent to these encouraging 
results, the authors conducted an RCT assessing efaproxiral in the treatment of BM from BC 
(ENRICH trial: Enhancing WBRT In patients with BC and hypoxic BM). However, the results of this 
trial in which 365 patients were enrolled, most of whom had two brain lesions, were negative [24]. 
Table 2. Radiosensitizers + WBRT vs. WBRT: randomized studies, including patients  
with BM from BC. 
Study Ref. Randomization arm N 
Primary 
(%) 
Median 
survival 
(months) 
6-Month 
survival 
Response 
Rate  
Komarnicky  
et al., 1991  
[19] 
30 Gy/6 fr + misonidazole  
30 Gy/6 fr  
30 Gy/10 fr + misonidazole  
30 Gy/10 fr 
196 
200 
190 
193 
L: NR 
B: NR 
O: NR 
3.1  
4.1  
3.9  
4.5 
68  
83  
65  
72 
NR 
Mehta  
et al., 2003 
[20] 
30 Gy/10 fr + MGd 193 L: 62% 5.1 82 
NR 
  B: 19%   
30 Gy/10 fr 208 O: 19% 5.8 85 
   p = 0.68  
Suh  
et al., 2006  
[21] 
30 Gy/10 fr + O2 + efaproxiral 265 L: 56% 5.4 
NR 
46 
  B: 21%  38 
30 Gy/10 fr + O2 250 O: 23% 4.4 p = 0.1 
   p = 0.16  
Knisely  
et al., 2008  
[22] 
37.5 Gy/15 fr + thalidomide 84 L: 62% 3.9 26% 
NR 
  B: 18%   
37.5 Gy/15 fr 92 O: 20% 3.9 28% 
    p = 0.88 
Abbreviations: N, number of patients; WBRT, whole brain radiation therapy; fr, fractions; L, lung; B, breast; 
O, other; NR, not reported; MGd, motexafin gadolinium. 
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2.4. Radio-Chemotherapy 
Although chemotherapy has traditionally played a limited role in the treatment of BM, predominantly 
due to its low potency to cross the blood brain barrier, it has been the subject of several studies for use 
in combination with WBRT, mainly for BM from lung cancer. However, only two RCTs comparing 
WBRT with or without concurrent chemotherapy (temozolomide) included patients with primary BC, 
and this population was widely underrepresented (Table 3) [25,26]. 
Table 3. Randomized studies (including patients with BM from BC) assessing WBRT + 
chemotherapy vs. WBRT alone. 
Study Ref. 
Randomization 
arm 
N Primary 
Median survival 
(months) 
Response 
rate 
Antonadou  
et al., 2002 
[25] 
40 Gy/20 fr 23 L: 83% 7.0 67% 
  B: 11%   
40 Gy/20 fr + TMZ 25 O: 6% 8.6 96% 
   NS (p = 0.017) 
Verger et al., 
2005 
[26] 
30 Gy/10 fr 41 L: 51% 3.1 32% 
  B: 16%   
30 Gy/10 fr + TMZ 41 O: 33% 4.5 32% 
   NS (p = NS) 
Abbreviations: N, number of patients; TMZ, temozolomide; L, lung; B, breast; O, other; NS, non-significant. 
These trials showed that at the best, there was an improvement in local control and an increased 
time to cerebral progression. However, this was at the cost of increased toxicity, and there was no 
improvement in survival. 
At the San Antonio Breast Cancer Symposium, 2011, Kirova et al. reported the results of a 
randomized phase II trial assessing WBRT with or without temozolomide as a radiosensitizer for 
patients with BM from BC [27]; no advantage in tumor control was found using the addition  
of temozolomide. 
Further trials assessing chemotherapy combined with targeted therapies and WBRT are currently 
under investigation. 
2.5. WBRT and Targeted Therapies 
Therapies targeting the human epidermal growth factor receptor 2 (HER2) have been evaluated or 
are currently under investigation in combination with WBRT for BMBC. 
Only one retrospective study on 31 patients showed the feasibility of the trastuzumab-WBRT 
combination with good tolerance and an encouraging objective response [28]. A recently completed 
open-label, non-randomized, multicenter trial has investigated the safety and efficacy of the 
trastuzumab-WBRT combination (NCT01363986) and should provide more information. 
The use of lapatinib concurrently with WBRT has been assessed in a feasibility phase I study for 
patients with BM from HER2-positive BC, but this study did not meet the predefined criteria for 
feasibility (upper bound of the dose-limiting toxicity: 95%; confidence interval: <30%) [29]. However, 
the combination of lapatinib with WBRT is currently being examined in two ongoing phase II studies 
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targeting patients with BM from primary lung or BC, with the main objective of evaluating the 
response rate (NCT01218529, NCT01622868). 
Finally, an ongoing feasibility phase I study is currently examining different sequences of  
combined trastuzumab emtansine (TDM-1) and WBRT in patients with BM from HER2-positive BC  
(brain radiation and TDM-1 in HER2-positive metastatic BC: BIRTH trial). 
2.6. Role of a Boost Added to WBRT 
The benefit of an SRS-boost as part of WBRT has been shown in patients with oligometastatic  
BM [30–32]. However, for multiple BM (>3), the addition of a boost did not lead to better results [15]. 
The Radiation Therapy Oncology Group (RTOG)-9508 trial (comprising only 10% of patients with 
BM from BC) showed that WBRT plus SRS was better than WBRT alone in terms of survival rates for 
patients with single BM and that there was a trend towards a survival benefit for patients with  
2–3 BM [30]. Kondziolka et al. conducted an RCT with a similar design, for patients with 2–4 BM [31]. 
The sample size was determined to detect a difference in the primary outcome measure of local control 
after radiosurgery plus WBRT, and only 27 patients were randomized. No survival advantage of a 
boost was noted, even though there was a trend towards longer survival in the boost arm, an increased 
time to progression (36 vs. 6 months, p = 0.0005) and a dramatic increase in the rate of one-year local 
control (92% vs. 8%, p = 0.0016). In a meta-analysis, involving 358 patients with 1–4 BM from 
unselected primary tumors, no significant difference was observed in the survival between the patients 
with or without a boost (HR = 0.82, 95% CI 0.65; 1.02) [32]. However, in the WBRT + SRS arms, 
patients with single BM had a significantly increased median overall survival (6.5 vs. 4.9 months,  
p = 0.04) and less local recurrence (HR = 0.27, 95% CI 0.14; 0.52) than the patients receiving only 
WBRT. In addition, a statistically significant improvement in Karnofsky performance status (KPS) and 
a decreased use of corticosteroids was observed. To our knowledge, there is no specific study for BM 
from BC in this context, but these data promote an additional SRS-boost for patients with 1–3 BM. 
However, if extra-cerebral disease is uncontrolled, giving a short life expectancy, the value of 
maximalist intra-cerebral control, and thus of a boost, remains questionable. 
Four ongoing prospective trials are currently assessing the interest in, or feasibility of, an integrated 
boost during WBRT (with or without hippocampal sparing) for patients with multiple BMs from 
mixed primaries (NCT00876759; NCT01414738; NCT01218542; and NCT01046123). 
2.7. Role of WBRT after Radiosurgery 
The value of WBRT in addition to an SRS procedure was the subject of two randomized phase III 
trials [33,34]. However, in these two trials, only 10% of the included population were patients with 
BM from BC. The study by Aoyama et al. [33] randomized 132 patients with a KPS ≥70 and 1–4 BM, 
to receive either SRS alone or SRS plus WBRT. At one year, patients receiving the combination had 
better local control (initial metastatic site) (88.7% vs. 72.5%, p = 0.002), better remote control in the 
brain (58.5% vs. 36.3% p = 0.003) and one-year actuarial survival not being significantly improved  
(38.5% vs. 28.4%, p = 0.42), but the median survival was similar. There was no difference in the 
neurological death rate and or incidence of toxicity (although, neurocognitive evaluations were 
lacking) between the two arms. The authors concluded that omission of WBRT was appropriate.  
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This study was the basis of a second analysis focusing on mini mental state examination (MMSE) 
change as a function of the treatment arm [35]. The MMSE score was available for 110 out of the  
132 enrolled patients. For patients with a baseline or post-treatment MMSE ≥27, the median time to 
MMSE decline was significantly longer in the combined therapy arm (16.5 vs. 7.6 months, p = 0.05), 
suggesting that the recurrence itself may be responsible for neurocognitive deterioration. 
Similar results were observed in the European Organization for Research and Treatment of Cancer 
(EORTC) trial, which included 199 patients with 1–3 BM who were randomized to SRS alone or  
SRS plus WBRT [34]. Upfront WBRT led to a significant decrease in brain failure rate (initial site: 
19% vs. 31%, p = 0.04; remote site: 33% vs. 48%, p = 0.023) and in neurological deaths, without any 
difference in functional independence time or survival. This study generated a second analysis 
reporting the quality of life and a self-reporting assessment of cognitive function [36]. A statistically 
significant and clinically meaningful difference in global health-related quality of life mean scores  
was detected at nine months in favor of patients who had observation alone, but this difference  
was transient and no longer observed at 12 months. However, the mean difference was statistically 
significant for cognitive functioning at 12 months (mean, 80.4; SE, 3.7 for observation vs. mean, 69.7; 
SE, 4.0 for WBRT; p = 0.0486). 
Finally, a retrospective trial suggested a survival advantage for patients with single BM and 
controlled extra-cranial disease who underwent SRS followed by WBRT, compared with those 
receiving only SRS [37]. 
The above is a summary of the literature related to the current debate regarding the best choice for 
patients with oligometastatic brain disease. On the one hand, since WBRT appears to significantly 
reduce the number of recurrent BMs, it could reasonably be concluded that the trial from  
Aoyama et al. [33] supports the use of upfront WBRT in the treatment of 1–4 BM; but on the other 
hand, opponents [34] argue that WBRT can be omitted, since it has no impact on survival, and 
recurrence might be successfully treated with salvage therapy, thus avoiding any neurotoxic effect in 
patients without relapse. 
An ongoing multicenter randomized phase III trial with the primary end-point of overall survival is 
assessing the neurocognitive effect of WBRT added to SRS for patients with 1–3 BM from unselected 
solid tumors as a secondary end-point (NCT00377156), in order to verify the results of the RCT from 
Chang et al. [38], which found that patients in the combined arm were significantly more impaired  
in one neurocognitive test at four months (52% vs. 24%). These interesting results required further 
investigations, as several biases were highlighted (such as the suboptimal time to neurocognitive 
assessment, a surprisingly high death rate in the combined arm, an imbalance in prognostic factors, 
baseline neurocognition and tumor volume). 
2.8. WBRT ± Surgery 
Surgery for BM has usually been considered only in cases of vital threat, major neurological risk or 
the need for histological diagnosis. For patients with a single BM, the treatment strategy has now been 
modified, based on the results of three RCTs [39–41]. In these trials, patients with a single BM were 
randomly assigned to receive either WBRT alone or surgery followed by WBRT (Table 4). 
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Table 4. WBRT vs. surgery + WBRT: randomized trials. 
Study Ref. BM treatment 
Radiation 
schedule 
Patients 
number 
Median survival 
(months) 
p 
Patchell et al., 
1990 
[39] 
Biopsy + WBRT 
Surgery + WBRT 
36 Gy/12 fr 
23  
25 
3.4  
9.2 
<0.01 
Vecht et al., 
1993 
[40] 
WBRT  
Surgery + WBRT 
40 Gy/20 BID 
31  
32 
6  
10 
0.04 
Mintz et al., 
1996 
[41] 
WBRT  
Surgery + WBRT 
30 Gy/10 fr 
43  
41 
6.3  
5.6 
0.24  
(NS) 
Abbreviations: WBRT, whole brain radiation therapy; BM, brain metastases; fr, fractions; BID, twice 
fractions daily; and NS, non-significant. 
These trials included a limited number of patients with BM from BC, but are the only trials to provide 
information related to this type of therapeutic strategy. Two of the trials showed an improvement in the 
median survival for patients with controlled extra-cranial metastases who underwent surgery, as well as a 
significant improvement in functionality (KPS ≥ 70: 38 vs. 8 weeks) [39,40,42]. The survival advantage 
was attributed to a decrease in neurological deaths, and this was not offset by systemic deaths when 
extra-cranial disease was controlled [39]. However, the third trial of Mintz et al. [41] did not show any 
survival advantage, but the fact that 73% of included patients had uncontrolled extra-cranial disease 
may explain this result. In addition, in this study, no patient received a cerebral MRI, making 
questionable the “single” brain metastasis definition, whereas all patients in the Patchell studies were 
actually assessed by MRI-scans. 
2.9. Surgery ± WBRT 
Surgery without upfront WBRT has also been evaluated in two RCTs, wherein 10% of the patients 
had BM from BC [34,43]. In these two trials, upfront WBRT led to a lower incidence of brain failure 
(initial site 10%–27% vs. 46%–59%; remote sites 14%–23% vs. 37%–42%) and neurological death  
(14%–28% vs. 44% without surgery), without any difference in overall survival. It could be expected 
that for patients with controlled extra-cranial disease, a survival advantage would emerge from the 
combined strategy. Less than half of the participating patients in both trials had controlled extra-cranial 
disease, and no subgroup analysis for survival was performed. Moreover, since the neurological death 
rate was significantly higher for patients with delayed WBRT in both studies, it appears that salvage 
therapy is less effective on brain control than upfront WBRT. 
Furthermore, two retrospective studies that included patients with single BM and no extra-cerebral 
disease showed a survival advantage for the group of patients receiving WBRT after BM  
surgical resection [44,45]. 
Other therapeutic strategies are currently under investigation, but have not yet been published in 
RCT, e.g., “on demand” SRS, surgery followed by tumor bed irradiation. 
3. Discussion 
To summarize, scarce data exists in relation to the management of BM, specifically from BC,  
the purpose of which ranges from maximal brain disease control to symptom palliation. It is 
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considered that, despite a relatively good response rate and good symptom palliation, WBRT alone 
remains insufficient in the treatment of oligometastatic brain disease and should be considered only for 
multiple (>4) BMs. 
The main dilemma relies on the use of WBRT after local treatment for oligometastatic brain disease 
(1–4 BM). Despite the benefits that would be delivered in terms of increased brain control, postponing 
WBRT after local treatment is considered to be a reasonable option, due to the lack of survival benefit 
from upfront WBRT, as has been discussed in the EORTC trial [34]. 
However, it is of note that, firstly, some data support the hypothesis that survival after a diagnosis 
of BM in patients with BC improves with the addition of modern multimodalities treatment [46];  
and secondly, it has been suggested that contrary to the effects in patients with BM from other solid 
tumors, half of the patients with BM from BC can die from neurological causes [47,48]. 
Participants in the EORTC trial consisted of 53% with BM from lung cancer, 12% with BM from 
BC and 35% with BM from other causes. Despite a statistically significant decrease in neurological 
deaths in patients who received upfront WBRT, the median survival was not altered. Death was 
considered as being from neurological causes if intracranial failure was a component of the cause of 
death. In other words, the death rate was the same in both arms, whatever the neurological status, 
meaning that the cause of death was not related to the brain disease, but rather to systemic disease. 
That is considered to be the reason why an improvement in brain control does not lead to prolonged 
survival. For patients whose lives are not jeopardized by uncontrolled systemic or primary disease,  
an improvement in brain control may lead to an increase in median survival, as suggested by some 
authors [37,44,45]. In the EORTC trial, the cerebral progression rate was 78% in the observation  
arm vs. 48% in the adjuvant WBRT arm (p = 0.002) [34]. Hence, it is reasonable to wonder whether 
the control of brain disease in patients with controlled extra-cranial disease might actually impact on 
their overall survival. Since the median survival of patients with BM from BC is proven to have 
doubled compared to other primaries, most likely due to the prolonged efficiency of systemic 
treatments [2], it seems crucial to reappraise the actual role of adjuvant WBRT in this population. For 
all the reasons specified here, the results of the BM RCTs (including mainly non-small cell lung 
cancers) should not be standardized for all histologies. 
Moreover, leptomeningeal disease (LMD), which is a well-known pattern of central nervous system 
(CNS) failure in patients with metastatic breast cancer, is usually associated with a very poor outcome. 
This failure pattern has been significantly associated with BC as the primary site in patients treated 
with SRS alone, and WBRT has been found to significantly lower this risk [49,50]. The one-year 
cumulative incidence of LMD has been estimated to be as high as 24% (95% CI, 9%–41%) for BC 
compared to 9% (95% CI, 5%–14%) for patients with a non-breast histology (p = 0.004) [50]. 
Some BC subtypes, such as HER2 and triple negative (HER2 negative and hormonal receptors 
negative), are at high risk of brain recurrence even after initial treatment [51,52], with the former more 
likely to have controlled extra-cranial disease, making brain control a major issue. 
Based on these findings, there are at least two arguments favoring upfront WBRT for oligometastatic 
brain disease from BC: firstly, the fact that patients with BC are more likely to have controlled 
systemic disease and are thus more exposed to suffering from neurological death; and secondly,  
the fact that leptomeningeal disease (which is a typical pattern of CNS failure in patients with BC) is 
associated with a very poor prognosis and quality of life, but its incidence is lowered by WBRT. 
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Opponents to upfront WBRT propose an “on demand” SRS strategy, in order to avoid potential 
neurotoxicity, with an MRI survey every three months. However, it is also known that brain recurrence 
negatively impacts neurocognitive function [35,53]. Furthermore, in some cases, after multiple SRS 
sessions, WBRT will be no longer possible due to the cumulative radiation toxicity risk. Finally, brain 
recurrence is not always accessible to SRS, and if so, WBRT will be mandatory, with less efficiency,  
due to the BM size; therefore, neurological deterioration could occur earlier than radio-induced toxicity. 
The problem with upfront WBRT concerns long-term neurotoxicities as assessed through RCTs [54]. 
The ideal strategy for oligometastatic brain disease would be a local treatment followed by  
a preventive systemic treatment, which still needs to be defined. Efforts are currently being developed 
to minimize WBRT neurotoxicity, while providing maximal brain control. Hence, the Radiation 
Therapy Oncology Group (RTOG) has recently reported the effectiveness of memantine (N-methyl- 
D-aspartate receptor antagonist) in preventing cognitive dysfunction following WBRT [55]; 
hippocampal sparing during WBRT is currently under investigation in three RCTs (NCT01227954, 
NCT01414738 and NCT01942980) with encouraging results emerging from a phase II trial from the 
RTOG presented at the American Society for Radiation Oncology (ASTRO) meeting 2013. 
4. Materials and Method 
Relevant studies were identified by searching the electronic database, Medlin/PubMed (National 
Library of Medicine, Bethesda, MA, USA), between January 2000 and September 2013, using the 
following keywords: WBRT, BM, BC. Reference lists from these sources were then manually 
searched to identify additional relevant publications. To be eligible for inclusion, studies had to meet 
the following criteria: published data on WBRT alone or combined with other treatments, in the 
management of newly diagnosed BM, either in the particular setting of BM from BC or in a general 
setting from which data for patients with primary BC (more than 20) were extracted and included in 
the study. As this review focuses on the efficiency of WBRT, studies on radiation therapy schedules 
and treatments combined with WBRT, such as local (surgery, radiosurgery and radiation boost), 
radiosensitizers, chemotherapy and targeted therapies, were also included. Articles were excluded from 
our review if they were non-English language papers, individual case reports, review articles, phase I 
and II trials for which phase III trials were already available, trials not assessing WBRT itself and 
studies not including patients with BM from BC. Data extracted from the studies were: the number of 
patients accrued and/or evaluated, the impact of therapeutic combinations and radiation therapy 
schedules on the response rate to treatments, overall survival and toxicity. 
The aim was to evaluate whether WBRT for patients with BM from BC is still considered to be an 
appropriate treatment. 
5. Conclusions 
When the benefit of controlling brain disease is not offset by active extra-cranial disease, there is an 
actual need for the use of aggressive treatments in patients with BM with controlled systemic disease. 
Due to the improvement of systemic disease treatment in BC, the overall survival of these patients has 
been significantly lengthened. Some particular molecular profiles of BC, such as HER2-positive and 
triple negative, are responsible for an increased incidence of BM. In these patients the survival rate is 
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actually associated with neurological death, making BM treatment in this population an actual 
challenge. Indeed, brain disease control in this specific population is crucial and potentially could 
impact overall survival. For these reasons, the findings of the EORTC phase III study should not be 
generalized to a particular population, and the upfront WBRT should be reappraised focusing on the 
impact of brain tumor control on overall survival. 
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